NCT04351620View on ClinicalTrials.gov

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

June 10, 2020

Study Completion Date

June 10, 2020

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT04351620 - High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 | Biotech Hunter | Biotech Hunter